RecruitingPhase 3NCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UCB Biopharma SRL
Principal Investigator: UCB Cares
001 844 599 2273 (UCB)
Intervention: DZP(drug)
Enrollment: 450 enrolled
Eligibility: 16 years · All sexes
Timeline: 2024 – 2028

Study locations (30)

Sl0044 50058, Avondale, Arizona, United States
Sl0044 50550, Chandler, Arizona, United States
Sl0044 50713, Gilbert, Arizona, United States
Sl0044 50662, Glendale, Arizona, United States
Sl0044 50052, Phoenix, Arizona, United States
Sl0044 50677, Scottsdale, Arizona, United States
Sl0044 50670, Searcy, Arkansas, United States
Sl0044 50737, Beverly Hills, California, United States
Sl0044 50775, Beverly Hills, California, United States
Sl0044 50257, La Jolla, California, United States
Sl0044 50275, La Palma, California, United States
Sl0044 50755, Los Alamitos, California, United States
Sl0044 50258, Los Angeles, California, United States
Sl0044 50725, Menifee, California, United States
Sl0044 50340, Orange, California, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06617325 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials